+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market (2022-2027) by Type and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 191 Pages
  • October 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5684364

Photonics-Enabled New Technologies Are Revolutionizing Epi Diagnostics Practices in the Medical Field

The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is estimated to be USD 4.76 Bn in 2022 and is expected to reach USD 6.71 Bn by 2027, growing at a CAGR of 7.1%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is segmented based on Type and Geography.
  • By Type, the market is classified into Therapeutics and Diagnostics.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Allergan PLC, Johnson & Johnson Services, Inc., Cilian Ag, Digestive Care, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

What is the estimated value of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market?

The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market was estimated to be valued at $4.76 Billion in 2022.

What is the growth rate of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market?

The growth rate of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is 7.1%, with an estimated value of $6.71 Billion by 2027.

What is the forecasted size of the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market?

The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is estimated to be worth $6.71 Billion by 2027.

Who are the key companies in the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market?

Key companies in the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market include AbbVie Inc., Allergan PLC, Nordmark Arzneimittel GmbH & Co. KG, Johnson & Johnson Services, Inc., Cilian Ag, First Wave BioPharma, Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Cilian Ag and Chiesi Farmaceutici S.p.A..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increase in the Prevalence of Cystic Fibrosis and Chronic Pancreatitis
4.1.2 An increase in the Prevalence of Diabetes is expected to Increase the Risk for EPI Significantly
4.2 Restraints
4.2.1 High Cost Associated with the Implementation of Predictive Analysis
4.2.2 Stringent FDA Regulations
4.3 Opportunities
4.3.1 Rise in Focus on Research & Development
4.4 Challenges
4.4.1 Lack of Skilled Expertise in Underdeveloped Countries
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Type
6.1 Introduction
6.2 Therapeutics
6.2.1 Pancreatic Enzyme Replacement Therapy (PERT)
6.2.2 Nutritional Therapy
6.3 Diagnostics
6.3.1 Blood Tests
6.3.2 Endoscopic Ultra-sonography (EUS)
6.3.3 Magnetic Resonance Imaging (MRI)
6.3.4 CT Scanning
7 Americas’ Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
7.1 Introduction
7.2 Argentina
7.3 Brazil
7.4 Canada
7.5 Chile
7.6 Colombia
7.7 Mexico
7.8 Peru
7.9 United States
7.10 Rest of Americas
8 Europe’s Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
8.1 Introduction
8.2 Austria
8.3 Belgium
8.4 Denmark
8.5 Finland
8.6 France
8.7 Germany
8.8 Italy
8.9 Netherlands
8.10 Norway
8.11 Poland
8.12 Russia
8.13 Spain
8.14 Sweden
8.15 Switzerland
8.16 United Kingdom
8.17 Rest of Europe
9 Middle East and Africa’s Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
9.1 Introduction
9.2 Egypt
9.3 Israel
9.4 Qatar
9.5 Saudi Arabia
9.6 South Africa
9.7 United Arab Emirates
9.8 Rest of MEA
10 APAC’s Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
10.1 Introduction
10.2 Australia
10.3 Bangladesh
10.4 China
10.5 India
10.6 Indonesia
10.7 Japan
10.8 Malaysia
10.9 Philippines
10.10 Singapore
10.11 South Korea
10.12 Sri Lanka
10.13 Thailand
10.14 Taiwan
10.15 Rest of Asia-Pacific
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 AbbVie Inc.
12.2 Allergan PLC
12.3 Nordmark Arzneimittel GmbH & Co. KG
12.4 Johnson & Johnson Services, Inc.
12.5 Cilian Ag
12.6 First Wave BioPharma
12.7 Digestive Care, Inc.
12.8 Janssen Pharmaceuticals, Inc.
12.9 Cilian Ag
12.10 Chiesi Farmaceutici S.p.A.
12.11 Abbott Laboratories
12.12 Adare Pharmaceuticals, Inc.
12.13 Mayoly Spindler
12.14 Solvay Pharmaceuticals, Inc.
12.15 Axcan Pharma, Inc.
12.16 OneCare Media, LLC
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • AbbVie Inc.
  • Allergan PLC
  • Nordmark Arzneimittel GmbH & Co. KG
  • Johnson & Johnson Services, Inc.
  • Cilian Ag
  • First Wave BioPharma
  • Digestive Care, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Cilian Ag
  • Chiesi Farmaceutici S.p.A.
  • Abbott Laboratories
  • Adare Pharmaceuticals, Inc.
  • Mayoly Spindler
  • Solvay Pharmaceuticals, Inc.
  • Axcan Pharma, Inc.
  • OneCare Media, LLC